Small molecule · Inhibitor of VEGFR2 (kinase insert domain receptor) (KDR) · developed by Bristol-Myers Squibb
Phase 1/2Most advanced trial (none active)
1Registered trials
What is Brivanib Alaninate?
Brivanib alaninate is the alaninate salt of brivanib, a small-molecule inhibitor that strongly binds and inhibits VEGFR2, a tyrosine kinase receptor expressed mainly on vascular endothelial cells. It is studied in advanced hepatocellular carcinoma, both alone and in combination with MGD013.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
MGD013, BMS-582664, BMS-582664-02
Drug type
Small molecule
Targets
VEGFR2 (kinase insert domain receptor) (KDR)
Mechanism
Inhibitor of VEGFR2 (kinase insert domain receptor) (KDR)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.